NCPDP advises on biosimilars
The National Council for Prescription Drug Programs took part in the meeting that may result in the rollout of the nation’s first biosimilar medication. John Klimek, senior vice president for standards and industry information technology at NCPDP, addressed the Food and Drug Administration’s Center for Drug Evaluation and Research (CDER) and Oncologic Drugs Advisory Committee (ODAC)
